C6O Stock Overview Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Clovis Oncology, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Clovis Oncology Historical stock prices Current Share Price US$0.091 52 Week High US$3.00 52 Week Low US$0.09 Beta 0.95 1 Month Change 0% 3 Month Change 0% 1 Year Change -94.05% 3 Year Change -97.84% 5 Year Change n/a Change since IPO -99.87%
Recent News & Updates
Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index Dec 22 Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index
Nasdaq to Delist Common Stock of Clovis Oncology from Exchange Dec 14 Clovis Oncology, Inc. Filed for Bankruptcy Dec 13
Clovis Oncology, Inc. Filed for Bankruptcy Dec 12
Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t Nov 18 See more updates
Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index Dec 22 Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index
Nasdaq to Delist Common Stock of Clovis Oncology from Exchange Dec 14 Clovis Oncology, Inc. Filed for Bankruptcy Dec 13
Clovis Oncology, Inc. Filed for Bankruptcy Dec 12
Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t Nov 18
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.56 loss in 3Q 2021) Nov 10
Clovis Oncology, Inc Announces Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress Oct 17
Cvis Oncncology, Inc. Announces Positive Top-Line Data from the Phase 3, Open-Label, Multicenter, Randomized Triton3 Trial Oct 04
Clovis Oncology, Inc. Submits Applications for Rubraca® Label Expansion in the US and European Union as First-Line Maintenance Treatment in Women with Advanced Ovarian Cancer Sep 14
Clovis Oncology’s Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups Sep 12
Second quarter 2022 earnings released: US$0.49 loss per share (vs US$0.61 loss in 2Q 2021) Aug 08
Clovis Oncology, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 21
Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting Jun 15
First quarter 2022 earnings released: US$0.43 loss per share (vs US$0.64 loss in 1Q 2021) May 05
Now 20% undervalued Apr 28
Insufficient new directors Apr 27
Now 20% undervalued after recent price drop Apr 23
Clovis Oncology, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 21
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022 Apr 09
Now 23% undervalued after recent price drop Mar 16
Clovis Oncology, Inc. Announces A Trial-In-Progress Poster Detailing the Phase 1 Portion of the LuMIERE Clinical Study for Its Targeted Radiotherapy Candidate FAP-2286 Feb 26
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 25
Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021 Jan 12
Insufficient new directors Dec 06
Third quarter 2021 earnings released: US$0.56 loss per share (vs US$0.89 loss in 3Q 2020) Nov 06
Clovis Oncology, Inc. Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland Aug 24
Clovis Oncology, Inc. Provides an Update on the Clinical Development Programs Aug 06
Second quarter 2021 earnings released: US$0.61 loss per share (vs US$1.15 loss in 2Q 2020) Aug 05
Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment Jun 24
Clovis Oncology, Inc. Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting May 21
First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 1Q 2020) May 08
Clovis Oncology, Inc. Announces First Presentation of Data from the Phase 3 ARIEL4 Study of Rubraca® (rucaparib) at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer Mar 21
Revenue beats expectations Feb 24
Full year 2020 earnings released: US$4.38 loss per share (vs US$7.43 loss in FY 2019) Feb 24
Clovis Oncology, Inc. Presents Data in Advanced Prostate Cancer At Asco 2021 Genitourinary Cancers Symposium Virtual Meeting Feb 12
New 90-day high: €8.10 Feb 08
New 90-day high: €4.77 Jan 19
Clovis Oncology, Inc. to Report Q4, 2020 Results on Feb 23, 2021 Jan 12
Clovis Oncology, Inc. Completes Submission of Two Investigational New Drug Applications to the U.S. Food and Drug Administration for FAP-2286 Dec 30
Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation Dec 23
Third quarter 2020 earnings released: US$0.89 loss per share Nov 06
Revenue misses expectations Nov 06 Clovis Oncology, Inc. announced that it expects to receive $50 million in funding
New 90-day low: €3.78 Nov 06 Shareholder Returns C6O DE Biotechs DE Market 7D 0% -0.3% 2.0% 1Y -94.1% -5.5% 15.0%
See full shareholder returns
Return vs Market: C6O underperformed the German Market which returned -13% over the past year.
Price Volatility Is C6O's price volatile compared to industry and market? C6O volatility C6O Average Weekly Movement n/a Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: C6O's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine C6O's volatility change over the past year.
About the Company Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Show more Clovis Oncology, Inc. Fundamentals Summary How do Clovis Oncology's earnings and revenue compare to its market cap? C6O fundamental statistics Market cap €12.78m Earnings (TTM ) -€233.87m Revenue (TTM ) €123.50m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) C6O income statement (TTM ) Revenue US$133.02m Cost of Revenue US$31.59m Gross Profit US$101.43m Other Expenses US$353.33m Earnings -US$251.91m
Last Reported Earnings
Sep 30, 2022
Earnings per share (EPS) -1.74 Gross Margin 76.25% Net Profit Margin -189.37% Debt/Equity Ratio -158.0%
How did C6O perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/03/22 00:31 End of Day Share Price 2022/12/23 00:00 Earnings 2022/09/30 Annual Earnings 2021/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Clovis Oncology, Inc. is covered by 18 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Tazeen Ahmad BofA Global Research Alethia Young Credit Suisse Steven Breazzano Evercore ISI
Show 15 more analysts 
